Clinical Trial

A Mutiple-dose Study of IBI3033 in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 8-week treatment period and 8-week follow-up period.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-05-27
Trial Details
NCT Number NCT07456839
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Healthy Participants
Enrollment 8 participants
Start Date 2026-03-18
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-11-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-26